Using omega-3 fatty acids and nutrition to support cancer patients with muscle loss
Omega-3 Enriched Supplements in the Nutritional Support of Patients With Gastrointestinal Cancer
This study is testing if omega-3 supplements can help cancer patients with muscle loss feel stronger and better during their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maimónides Biomedical Research Institute of Córdoba Academic / other |
| Locations | 1 site (Córdoba, Cordoba) |
| Trial ID | NCT06015971 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of omega-3 enriched nutritional supplements on patients with gastrointestinal cancer who are experiencing sarcopenia, a condition characterized by muscle loss and weakness. The approach involves providing oral nutritional supplements that may enhance immune function and improve overall nutritional status. Patients undergoing systemic treatments such as chemotherapy or immunotherapy will be monitored for changes in muscle mass and strength. The goal is to determine if nutritional support can improve treatment tolerance and quality of life for these patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-85 with gastrointestinal tumors who have experienced significant weight loss while undergoing systemic cancer treatments.
Not a fit: Patients with a life expectancy of less than two weeks or those with severe comorbidities affecting their ability to exercise may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance muscle strength and overall health in cancer patients, potentially improving their treatment outcomes and quality of life.
How similar studies have performed: Previous studies have shown promising results with nutritional interventions in cancer patients, suggesting that this approach may be beneficial, although the specific use of omega-3 in this context is less commonly tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Patients with Gastrointestinal tumor undergoing systemic treatment (chemo-radio-immuno therapy or their combination) * Body weight loss \>5% in the previous three months or \>10% in the previous six months * Both sexes * Age between 18-85 y-old. Exclusion Criteria: * Life expectancy \< 2 weeks * MDRD \< 15 mL/min * End-stage liver disease * Any musculoskeletal, cardiovascular and/or neurological disorders that could affect exercising.
Where this trial is running
Córdoba, Cordoba
- Imibic — Córdoba, Cordoba, Spain (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.